Home › Episona Raises $4M for Commercial Expansion of Epigenetic Male Fertility Test

Episona Raises $4M for Commercial Expansion of Epigenetic Male Fertility Test

Jun 06, 2017

NEW YORK (GenomeWeb) – Episona announced today that it has raised approximately $4 million in seed financing to support the expansion of its first commercial product, Seed — an epigenetic test for male infertility and embryo quality.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Clinical Lab Management

  1. Sonic Healthcare to Acquire Anatomical Pathology Provider Aurora Diagnostics

  2. TriCore Markets Lab Analytics as Standalone Service to Payors

    Premium

  3. Lab Industry Organizations File Amicus Briefs in Support of ACLA's PAMA Lawsuit

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.